All posts by psufka

Guidelines on Perioperative Management of Antirheumatic Medication for Hip & Knee Arthroplasty

After a brief summer break, #RheumJC is back!

Our next session will be Thursday, July 27th, discussing the recently published guidelines in Arthritis Care & Research: 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Effect of methotrexate discontinuation on efficacy of influenza vaccination in RA

This week’s #RheumJC will be Thursday, May 25th, discussing the May 2017 Annals of the Rheumatic Diseases article: Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial by Dr. Jin Kyun Park, et al.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Spinal Manipulation in the Treatment of Low Back Pain

Our next #RheumJC discussion will be Thursday, April 27th, discussing the April 2017 JAMA article: Association of Spinal Manipulative Therapy With Clinical Benefit and Harm for Acute Low Back Pain: Systematic Review and Meta-analysis by Dr. Neil M. Paige, et al.

The publisher has graciously made this article free to access on April 26–27.

We also suggest the accompanying editorial: The Role of Spinal Manipulation in the Treatment of Low Back Pain.

Please note, our second session will be held one hour earlier than our usual time.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Changes in Ultrasonographic Vascularity with Adalimumab + MTX in RA

Our next #RheumJC discussion will be Thursday, March 30th, discussing the recent November 2016 Arthritis & Rheumatology article: Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate) by Dr. Gurjit S. Kaeley, et al. This article is open-access.

As an additional reference, we suggest the Nature Reviews Rheumatology article: Using ultrasonography to facilitate best practice in diagnosis and management of RA.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

Use of Lesinurad with Allopurinol for Gout

Our next #RheumJC discussion will be Thursday, February 23rd, discussing the January 2017 Arthritis & Rheumatology article: Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study) by Dr. Kenneth G. Saag, et al. This article is open-access.

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

#RheumJC joining #NephJC to look at the PRECISION Trial

Artwork by Holly Fischer [CC BY 3.0 (http://creativecommons.org/licenses/by/3.0)], via Wikimedia Commons.

For our next journal club activity, we’ll be teaming up with the Nephrology Journal Club #NephJC to discuss the PRECISION Trial, published in NEJM: Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis by Nissen SE, et al. This article is open access via the NephJC blog post.

As many of you may recall, a portion of this data was presented during the #ACR16 late breaking abstract session: 1L: The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis.

When:

Additional Details:

  • For this session, we’ll plan on using the #NephJC hashtag for the discussion, since they’ll be hosting the session.
  • As usual, we suggest using the website tchat.io in your desktop web browser as the best way to participate in the chat.

Favorite Abstracts from the 2016 ACR Annual Meeting

640px-tnf-alpha

The next session of #RheumJC will be Wednesday, December 14. We’ll be discussing four of your favorite abstracts from the 2016 ACR Annual Meeting based on your votes from our recent poll.

The abstracts we’ll be discussing are:

Abstract 911 – Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (48%, 14 Votes)

Abstract 1955 – Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (41%, 12 Votes)

Abstract 3028 – A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (38%, 11 Votes)

Abstract 1725 – Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (34%, 10 Votes)

If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.

 

 

Poll: What #ACR16 abstracts should we discuss for the next journal club?

acr16-posterHope everyone had a great time at #ACR16! (In real life or virtually on Twitter)

Greetings and Happy Holidays #RheumJC friends!

For our next session of #RheumJC, we’ll be discussing some of our favorite abstracts from #ACR16. Since we were only able to narrow our list down to 9 abstracts among our team, we’re polling you to decide which abstracts we’ll be discussing for the next journal club.

Also, in hopes of increasing everyone’s ability to participate, we’re also polling on what day of the week and times that work best for you. Over the next year of #RheumJC, we’ll likely plan on mixing up the day of the week and time so that over time everyone has an opportunity to participate.

If you would like to see the full abstract, please check acrabstracts.org (unfortunately, our polling plugin doesn’t allow links).

What #ACR16 abstracts should #RheumJC discuss for the next journal club? (Choose up to 4)

  • 911 - Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. (18%, 14 Votes)
  • 1955 - Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months (16%, 12 Votes)
  • 3028 - A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA. (14%, 11 Votes)
  • 1725 - Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis (13%, 10 Votes)
  • 3225 - Dual Cytokine Inhibition with ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain Immunoglobulin (DVD-Ig™): Results from a 24-Week Open-Label Extension Study in Patients with RA (12%, 9 Votes)
  • 3169 - Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study (9%, 7 Votes)
  • 1957 - No Increased Risk of Chronic Kidney Disease with Allopurinol Use (8%, 6 Votes)
  • 86 - Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture (5%, 4 Votes)
  • 2987 - Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study (4%, 3 Votes)

Total Voters: 29

Loading ... Loading ...

What day of the week should we hold #RheumJC? (choose all days that would work for you)

  • Wednesday (19%, 9 Votes)
  • Thursday (19%, 9 Votes)
  • Tuesday (15%, 7 Votes)
  • Sunday (13%, 6 Votes)
  • Friday (13%, 6 Votes)
  • Monday (11%, 5 Votes)
  • Saturday (11%, 5 Votes)

Total Voters: 19

Loading ... Loading ...

What time of day would best allow you to participate in #RheumJC? (choose all times that would work for you)

  • 8p-10p Eastern / 1a-3a GMT (22%, 8 Votes)
  • 2p-4p Eastern / 7p-9p GMT (19%, 7 Votes)
  • 4p-6p Eastern / 9p-11p GMT (16%, 6 Votes)
  • 6p-8p Eastern / 11p-1a GMT (14%, 5 Votes)
  • 12p-2p Eastern / 5p-7p GMT (8%, 3 Votes)
  • 8-10am Eastern / 1p-3p GMT (5%, 2 Votes)
  • 10am-12p Eastern / 3p-5p GMT (5%, 2 Votes)
  • 10p-12a Eastern / 3a-5a GMT (3%, 1 Votes)
  • 2a-4a Eastern / 7a-9a GMT (3%, 1 Votes)
  • 4a-6a Eastern / 9a-11a GMT (3%, 1 Votes)
  • 6a-8a Eastern / 11a-1p GMT (3%, 1 Votes)
  • 12a-2a Eastern / 5a-7a GMT (0%, 0 Votes)

Total Voters: 17

Loading ... Loading ...

If you need to convert the listed time to your time zone, please use thetimezoneconverter.com.

Real World RA Treatments: Using a 2nd anti-TNF or a non-anti-TNF after primary failure of 1st anti-TNF

tnf-protein

Bonjour #RheumJC friends,

We’re pleased to announce our next journal club session will be Thursday, October 27th, discussing the JAMA article: Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial by Dr. Jacques-Eric Gottenberg, et al.

Dr. Gottenberg, will be joining us for the first one-hour session.

Dr. Gottenberg (@jegotten) is a staff rheumatologist with the Department of Rheumatology, National Reference Center for Systemic Autoimmune Diseases, Strasbourg University Hospital, Université de Strasbourg, Strasbourg, France.

JAMA has graciously made Dr. Gottenberg’s article and the related article free to access for 48 hours beginning October 26th

If you’re new to this, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.

We strongly suggest using the website tchat.io as the best way to participate in the chat by typing in the #RheumJC hashtag to join the discussion.

As always:

  1. Please remember to try to stay on topic whenever possible.
  2. Be polite and courteous.
  3. Do not violate HIPAA.

We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.